Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Bao, Weike ^a   Holt, Lucy J ^b   Prince, Rob D ^b   Jones, Gavin X ^b   Aravindhan, Karpagam ^a   Szapacs, Mathew ^c   Barbour, April M ^d   Jolivette, Larry J ^a   Lepore, John J ^a   Willette, Robert N ^a   DeAngelis, Elena ^b   Jucker, Beat M ^a  

^a GLAXOSMITHKLINE   (United States)

^b Biopharm Research   (United Kingdom)

^c DMPK   (United States)

^d Clinical Pharmacology Modelling and Stimulation   (United States)

Author keywords

Anti albumin binding domain antibody; Cardioprotection; Exendin 4; Glucagon like peptide 1 (GLP 1); Rat

Indexed keywords

ALBUMIN ANTIBODY; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; FUSION PROTEIN GALBUDAB; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] A8G; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HYBRID PROTEIN; INSULIN; LACTIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; FOOD INTAKE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA HALF LIFE; RAT; REPERFUSION INJURY; REPORTER GENE; SINGLE DRUG DOSE; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; IMMUNOCONJUGATES; INJECTIONS, SUBCUTANEOUS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SERUM ALBUMIN; SINGLE-DOMAIN ANTIBODIES; VENOMS; VENTRICULAR FUNCTION, LEFT;

EID: 84885339157     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-148     Document Type: Article

References (41)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-57. 10.1053/j.gastro.2007.03.054, 17498508.
2. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 2009, 70(3):343-53. 10.1111/j.1365-2265.2008.03396.x, 18771570.
3. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. Br J Pharmacol 2009, 157(8):1340-51. 10.1111/j.1476-5381.2009.00376.x, 2765323, 19681866.
4. Wei Y, Mojsov S. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol 1996, 8(11):811-7.
5. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54(1):146-51. 10.2337/diabetes.54.1.146, 15616022.
6. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317(3):1106-13. 10.1124/jpet.106.100982, 16489128.
7. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005, 19(1):9-11. 10.1007/s10557-005-6892-4, 15883751.
8. Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011, 43(5):300-5. 10.1055/s-0031-1271777, 21360419.
9. Dokken BB, Piermarini CV, Teachey MK, Gura MT, Dameff CJ, Heller BD, Krate J, Ashgar AM, Querin L, Mitchell JL, Hilwig RW, Kern KB. Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects. Am J Physiol Heart Circ Physiol 2013, 304(4):H538-H546. 10.1152/ajpheart.00282.2012, 23241323.
10. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117(18):2340-50. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
11. Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011, 6(8):e23570. 10.1371/journal.pone.0023570, 3162574, 21887274.
12. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109(8):962-5. 10.1161/01.CIR.0000120505.91348.58, 14981009.
13. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12(9):694-9. 10.1016/j.cardfail.2006.08.211, 17174230.
14. Neumiller JJ. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovasc Hematol Agents Med Chem 2012, 10(4):276-88. 10.2174/187152512803530379, 22827291.
15. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009, 49 Suppl 1:S16-S29.
16. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50(5):583-9. 10.1053/meta.2001.22519, 11319721.
17. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006, 30(9):1332-40. 10.1038/sj.ijo.0803284, 16534527.
18. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53(6):501-10. 10.1016/j.jacc.2008.10.033, 19195607.
19. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes DG. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010, 9:76. 10.1186/1475-2840-9-76, 2996354, 21080957.
20. Lonborg J, Kelbaek H, Vejlstrup N, Botker HE, Kim WY, Holmvang L, Jorgensen E, Helqvist S, Saunamaki K, Terkelsen CJ, Schoos MM, Kober L, Clemmensen P, Treiman M, Engstrom T. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012, 5(2):288-95. 10.1161/CIRCINTERVENTIONS.112.968388, 22496084.
21. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 2008, 356(1-2):231-8.
22. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32(10):1880-6. 10.2337/dc09-0366, 2752910, 19592625.
23. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008, 21(5):283-8. 10.1093/protein/gzm067, 18387938.
24. Rycroft D, Holt LJ. Methods for determining the PK parameters of AlbudAbs and of long serum half-life drugs made using the AlbudAb technology. Methods Mol Biol 2012, 911:457-73.
25. Walker A, Dunlevy G, Rycroft D, Topley P, Holt LJ, Herbert T, Davies M, Cook F, Holmes S, Jespers L, Herring C. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel 2010, 23(4):271-8. 10.1093/protein/gzp091, 20093262.
26. Coppieters K, Dreier T, Silence K, De Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006, 54(6):1856-66. 10.1002/art.21827, 16736523.
27. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002, 303(2):540-8. 10.1124/jpet.102.037002, 12388634.
28. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng 2001, 14(8):529-32. 10.1093/protein/14.8.529, 11579220.
29. Himmler A, Stratowa C, Czernilofsky AP. Functional testing of human dopamine D1 and D5 receptors expressed in stable cAMP-responsive luciferase reporter cell lines. J Recept Res 1993, 13(1-4):79-94.
30. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002, 30(2):E9. 10.1093/nar/30.2.e9, 99848, 11788735.
31. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 2003, 108(19):2393-9. 10.1161/01.CIR.0000093187.42015.6C, 14557369.
32. Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, Ohlstein EH, Willette RN. In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther 2008, 325(2):466-74. 10.1124/jpet.107.135327, 18287212.
33. Ye Y, Birnbaum Y. Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on " Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a" Am J Physiol Cell Physiol 2013, 304(6):C505-C507. 10.1152/ajpcell.00419.2012, 23364263.
34. Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, Walsh B, Diamant M, Cirincione B, Kothare P, Li WI, MacConell L. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011, 50(1):65-74. 10.2165/11585880-000000000-00000, 21142268.
35. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374(9683):39-47. 10.1016/S0140-6736(09)60659-0, 19515413.
36. Ravassa S, Zudaire A, Diez J. Glucagon-like peptide 1 and cardiac cell survival. Endocrinol Nutr 2012, 59(9):561-9. 10.1016/j.endonu.2012.07.007, 23031433.
37. Birnbaum Y, Ye Y, Bajaj M. Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. Metab Syndr Relat Disord 2012, 10(6):387-90. 10.1089/met.2012.0095, 22985024.
38. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146(1-3):243-9.
39. Ku HC, Chen WP, Su MJ. DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 2011, 384(2):197-207. 10.1007/s00210-011-0665-3, 21748358.
40. Xiao YF, Nikolskaya A, Jaye DA, Sigg DC. Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 2011, 10:6. 10.1186/1475-2840-10-6, 3037307, 21251280.
41. Velmurugan K, Balamurugan AN, Loganathan G, Ahmad A, Hering BJ, Pugazhenthi S. Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB. Endocrinology 2012, 153(3):1116-28. 10.1210/en.2011-1895, 22253425.